From: A systematic review of the effectiveness of policies restricting access to pregabalin
 | Margolis et al., 2009 [27 | Margolis, et al., 2010 [28] | Bazalo et al., 2010 [26] | Udall et al., 2014 [30] | Suehs et al., 2014 [31] | Placzek et al., 2014 [29] | Null et al., 2016 [32] | Martin et al., 2016 [33] |
---|---|---|---|---|---|---|---|---|
Pregabalin utilization | Significantly lower utilization in restricted cohort (PÂ <Â 0.01) | Significantly lower utilization in restricted cohort (PÂ <Â 0.001) | Not applicable (modeling) | Significantly lower utilization in restricted cohort (PÂ =Â 0.008) | Significantly lower utilization in restricted cohort (PÂ <Â 0.001) | No significant difference in utilization in either pDPN (PÂ =Â 0.731) or FM (PÂ =Â 0.192) | Significant increase in commercial plans before (PÂ <Â 0.001), but decrease after (PÂ <Â 0.001) ST started. Small numeric decrease after ST lifted (PÂ =Â 0.568) | Significant decrease with mail order, and increase without (PÂ <Â 0.001) |
All-cause pharmacy costs | Not evaluated | Not evaluated | Not evaluated | No significant differences in costs (PÂ =Â 0.197) | No significant differences in costs (PÂ =Â 0.14) | No significant differences in cost for either FM (PÂ =Â 0.835) or pDPN (PÂ =Â 0.846) | Not evaluated | No significant differences in costs (PÂ =Â 0.888) |
All-cause healthcare costs | Not evaluated | Not evaluated | Not evaluated | Significantly higher ($1222) in restricted cohort (PÂ =Â 0.016) | No significant difference in costs (PÂ =Â 0.35) | No significant differences in costs for either FM (PÂ =Â 0.667) or pDPN (PÂ =Â 0.625) | Not evaluated | No significant difference (PÂ =Â 0.474) |
Disease-related pharmacy costs | Significantly higher ($274) in restricted cohort (PÂ <Â 0.001) | No significant differences in costs (PÂ =Â 0.25) | Potential savings in the restricted plan were <Â 2% | No significant differences in costs (PÂ =Â 0.120) | Significantly higher ($12) in restricted cohort (PÂ <Â 0.001) | No significant differences in costs for either FM (PÂ =Â 0.948) or pDPN (PÂ =Â 0.946) | Not evaluated | Not evaluated |
Disease-related total healthcare costs | Significantly higher ($418) in restricted cohort (PÂ <Â 0.01) | No significant differences in costs (PÂ =Â 0.41) | Not evaluated | Significantly higher ($859) in restricted cohort (PÂ =Â 0.002) | No significant differences in cost (PÂ =Â 0.23) | No significant differences in cost for either FM (PÂ =Â 0.419) or pDPN (PÂ =Â 0.431) | Significantly lower (Medicare, PÂ <Â 0.001) after ST start, but with a rising trend over the analysis period | Not evaluated |